Acadia Pharmaceuticals (ACAD) Cost of Revenue (2016 - 2026)

Acadia Pharmaceuticals' Cost of Revenue history runs 11 years deep, the most recent figure standing at $24.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 21.57% year-over-year to $24.8 million; the TTM figure through Mar 2026 stood at $93.4 million (up 17.8% YoY), while the FY2025 annual figure was $89.0 million, up 8.75% from the prior year.
• Cost of Revenue for Q1 2026 stood at $24.8 million, down from $26.2 million in the prior quarter.
• The five-year high for Cost of Revenue was $26.2 million in Q4 2025, with the low at $1.7 million in Q1 2023.
• The 5-year median for Cost of Revenue is $18.2 million (2024), against an average of $14.6 million.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue slumped 77.54% in 2022, then jumped 1276.78% in 2024.
• Acadia Pharmaceuticals' Cost of Revenue stood at $2.4 million in 2022, then soared by 641.44% to $17.9 million in 2023, then advanced by 21.87% to $21.8 million in 2024, then gained by 20.28% to $26.2 million in 2025, then dropped by 5.47% to $24.8 million in 2026.
• Business Quant data shows ACAD's Cost of Revenue at $24.8 million in Q1 2026, $26.2 million in Q4 2025, and $21.6 million in Q3 2025.